{
    "2020-11-25": [
        [
            {
                "time": "",
                "original_text": "带量集采、医保目录谈判开启，大降价逃不掉，医药股还好吗？",
                "features": {
                    "keywords": [
                        "带量集采",
                        "医保目录",
                        "谈判",
                        "大降价",
                        "医药股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【医药】阿斯利康新冠疫苗达到主要功效终点，医药进入配置阶段——医药行业周报——中性",
                "features": {
                    "keywords": [
                        "阿斯利康",
                        "新冠疫苗",
                        "主要功效终点",
                        "医药",
                        "配置阶段"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}